Krystal Biotech, Inc. Share Price
KRYSKrystal Biotech, Inc. Stock Performance
Open $275.17 | Prev. Close $271.56 | Circuit Range N/A |
Day Range $263.63 - $275.17 | Year Range $122.80 - $295.98 | Volume 15,511 |
Average Traded $269.52 |
Krystal Biotech, Inc. Share Price Chart
About Krystal Biotech, Inc.
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Krystal Biotech, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
06-Feb-26 | $275.17 | $272.71 | +1.82% |
05-Feb-26 | $266.25 | $267.84 | -0.42% |
04-Feb-26 | $275.27 | $268.97 | -3.76% |
03-Feb-26 | $281.10 | $279.49 | -1.11% |
02-Feb-26 | $279.99 | $282.63 | +1.23% |
30-Jan-26 | $281.44 | $279.19 | -0.15% |
29-Jan-26 | $275.82 | $279.60 | +2.56% |